| Wednesday
| Thursday | Saturday
| Sunday |
| FRIDAY, DECEMBER
12, 2008 |
| 7:00-9:00 |
POSTER
DISCUSSION 3 & CONTINENTAL BREAKFAST - Ballroom
A |
|
| |
Circulating Tumor Cells & Marrow Micrometastases |
301-307 |
| |
|
|
| 7:00-9:00 |
POSTER DISCUSSION 4 & CONTINENTAL BREAKFAST - Ballroom B |
|
| |
Novel Targeted Therapies |
401-407 |
| |
|
|
| 7:00-9:00 |
POSTER
SESSION 2 & CONTINENTAL BREAKFAST - Exhibit Hall B
(#2001-2162) |
|
| |
|
|
| |
Detection/Diagnosis |
|
| |
Biopsy Techniques
Circulating Markers
Animal Models
|
2001-2002
2003-2006
2007-2012 |
| |
Tumor Cell and Molecular Biology |
|
| |
Drug Resistance
Genomics
Molecular Profiles
Tumor Progression, Invasion and Metastasis
|
2013-2019
2020-2024
2025-2041
2042-2065 |
| |
Prognosis and Response Prediction |
|
| |
Biomarkers - Methods
Other
|
2066-2071
2072-2085
|
| |
Risk, Epidemiology and Prevention |
|
| |
Ethnic/Racial Aspects
|
2086-2097
|
| |
Social, Behavioral, Economic and Outreach Studies |
|
| |
Doctor-Patient Communication
Education
|
2098-2100
2101-2105 |
| |
Treatment |
|
| |
Adjuvant Therapy - Targeted
Adjuvant Therapy - Other
Novel Targets and Targeted Agents
New Drugs and Treatment Strategies
|
2106-2111
2112-2118
2119-2130
2131-2162 |
| |
|
|
| 9:00-9:30 |
PLENARY LECTURE 2 –
Exhibit Hall D |
|
| |
|
|
| |
Detection, clinical relevance and specific biological properties of disseminating cancer cells in breast cancer patients
Klaus Pantel, MD
University Medical Center Hamburg-Eppendorf Institute of Tumor Biology
Hamburg, GERMANY
|
|
| |
|
|
| 9:30-11:15 |
GENERAL SESSION 3 –
Exhibit Hall D |
|
| |
Dennis Slamon, MD, PhD, Co-Moderator
David Geffen School of Medicine, Los Angeles, CA
and
Rachel Schiff, PhD, Co-Moderator
Baylor College of Medicine, Houston, TX |
|
| |
|
|
| 9:30 |
31. Neoadjuvant trastuzumab in patients with
HER2-positive locally advanced breast cancer:
primary efficacy analysis of the NOAH trial
Gianni L, Eiermann W, Semiglazov V, Manikhas GM,
Lluch A, Tjulandin S, Feyereislova A, Valagussa P, Baselga
J. Istituto Nazionale Tumori Milano, Italy; Frauenklinik
Vom Roten Kreuz, Munich, Germany; NN Petrov
Research Institute of Oncology, St Petersburg, Russian
Federation; City Oncology Hospital, St Petersburg,
Russian Federation; Hospital Clínico Universitario de
Valencia, Spain; NN Blokhin Russian Cancer Research
Centre, Moscow, Russian Federation; F Hoffmann-La
Roche, Basel, Switzerland; Fondazione Michelangelo,
Milan, Italy; Vall d’Hebron University Hospital, Barcelona,
Spain.
|
|
| |
|
|
| 9:45 |
32. HER2 protein expression predicts response to trastuzumab in
FISH-positive patients
Lipton A, Ali SM, Leitzel K, Koestler W, Fuchs E-M, Weidler J, Wu E, Sperinde
J, Chappey C, Huang W, Bates M. Penn State/Hershey Medical Center,
Hershey, PA; Lebanon VA Medical Center, Lebanon, PA; Medical University
of Vienna, Vienna, Austria; Monogram Biosciences, South San Francisco, CA. |
|
| |
|
|
| 10:00 |
33. A phase II study of trastuzumab-DM1, a first-in-class HER2
antibody-drug conjugate, in patients with HER2+ metastatic breast
cancer
Vukelja S, Rugo H, Vogel C, Borson R, Tan-Chiu E, Birkner M, Holden SN,
Klencke B, O’Shaughnessy J, Burris HA. US Oncology Research, Tyler Cancer
Center, Tyler TX; UCSF Comprehensive Cancer Center, San Francisco CA;
Lynn Cancer Institute, Boca Raton, FL; St. Louis Cancer & Breast Institute,
St. Louis, MO; Florida Cancer Care, Tamarac, FL; Genentech, Inc, South San
Francisco, CA; US Oncology Research, Baylor-Sammons Cancer Center,
Dallas, TX; Sarah Cannon Cancer Center, Nashville, TN.
|
|
| |
|
|
| 10:15 |
34. PI3 kinase activation and response to trastuzumab or lapatinib in
HER-2 overexpressing locally advanced breast cancer (LABC)
Migliaccio I, Gutierrez MC, Wu M-F, Wong H, Pavlick A, Hilsenbeck SG,
Horlings HM, Rimawi M, Berns K, Bernards R, Osborne CK, Arteaga CL,
Chang JC. Baylor College of Medicine, Houston, TX; Vanderbilt University,
Nashville, TN; The Netherlands Cancer Institute, Netherlands.
|
|
| |
|
|
| 10:30 |
35. Transforming growth factor beta engages TACE/ADAM17 and
ErbB3 to activate PI3K/Akt in HER2-overexpressing breast cancer and
desensitizes cells to trastuzumab
Arteaga CL, Wang E, Xiang B, Olivares MG, Chung C. Vanderbilt University,
Nashville, TN. |
|
| |
|
|
| 10:45 |
36.
TOP2A, TIMP-1 and responsiveness to adjuvant anthracycline containing chemotherapy in high risk breast cancer patients
Ejlertsen B, Jensen M-B, Nielsen KV, Balslev E, Willemoe GL, Hertel PB, Knoop AS, Mouridsen HT, Brünner N. Danish Breast Cancer Cooperative Group, Rigshospitalet, Copenhagen, Denmark; Dako A/S, Glostrup, Denmark; Veterinary Pathobiology, Faculty of Life Sciences, University of Copenhagen, Denmark.
|
|
| |
|
|
| 11:00 |
37. Neratinib (HKI-272), an irreversible pan erbB receptor tyrosine
kinase inhibitor: phase 2 results in patients with advanced HER2+
breast cancer
Burstein HJ, Sun Y, Tan AR, Dirix L, Vermette JJ, Powell C, Zacharchuk C,
Badwe RA. Dana Farber Cancer Institute, Boston, MA; Cancer Institute and
Hospital, Chinese Academy of Medical Sciences, China; Cancer Institute
of New Jersey, New Brunswick, NJ; Oncology Center AZ St-Augustinus,
Antwerp, Belgium; Wyeth Research, Cambridge, MA; Tata Memorial
Hospital, Mumbai, India. |
|
| |
|
|
| 11:15-12:00 |
WILLIAM L. MCGUIRE MEMORIAL
LECTURE – Exhibit Hall D |
|
| |
Supported by an educational grant from GlaxoSmithKline |
|
| |
What is Cancer? How Modern Molecular Science is Challenging
Traditional Views
Larry Norton, MD
Memorial Sloan-Kettering Cancer Center
New York, NY
|
|
| |
|
|
| 12:00-1:45 |
LUNCH [Ticket Required] – Exhibit Hall A |
|
| |
|
|
| 12:30-1:45 |
CASE DISCUSSION 1 – Ballroom A |
|
| |
Jenny Chang, MD, Moderator, Baylor College of
Medicine
Ian Smith, MD, FRCP, Royal Marsden Hospital and
Institute of
Cancer Research
Gabriel Hortobagyi, MD, MD Anderson Cancer Center
James Ingle, MD, Mayo Clinic
Monica Morrow, MD, FACS, Memorial Sloan Kettering Cancer Center
Jessica Leung, MD, Univ of California, San Francisco
Jay Harris, MD, Harvard Medical School |
|
| |
|
|
| 12:30-1:45 |
BASIC SCIENCE PANEL DISCUSSIONS - Ballroom B |
|
| |
Breast Cancer Stem Cells: To believe or not to believe?
Jeffrey Rosen, MD, PhD, Moderator
Baylor College of Medicine
Houston, TX
Molecular targets in breast cancer stem cells
Max Wicha, MD
University of Michigan
Ann Arbor, MI
Breast tumor evolution
Kornelia Polyak, MD, PhD
Dana-Farber Cancer Institute
Boston, MA
|
|
| |
|
|
| 2:00-3:30 |
MINI-SYMPOSIUM 2 – Exhibit
Hall D |
|
| |
|
|
| |
MOLECULAR PROFILING FOR GUIDING THERAPEUTIC DECISIONS |
|
| |
Suzanne A.W. Fuqua, PhD, Co-Moderator
Baylor College of Medicine
Houston, TX
and
Laura van’t Veer, PhD , Co-Moderator
Netherlands Cancer Institute
Amsterdam, NETHERLANDS
|
|
| |
|
|
| 2:00 |
Introduction |
|
| |
|
|
| 2:00 |
RNA
|
|
| |
Laura van’t Veer, PhD
Netherlands Cancer Institute
Amsterdam, NETHERLANDS
|
|
| |
|
|
| 2:30 |
Systems approach to personalized molecular medicine |
|
| |
Gordon B. Mills, MD, PhD
UT MD Anderson Cancer Center
Houston, TX
|
|
| |
|
|
| 3:00 |
Predictors of Response to Adjuvant Therapy
|
|
| |
W. Fraser Symmans, MD
UT MD Anderson Cancer Center
Houston, TX |
|
| |
|
|
| 3:30-5:00 |
GENERAL SESSION 4–
Exhibit Hall D |
|
| |
|
|
| 3:30 |
41. A comparative genomic analysis between human breast cancer
and paired tumor lines derived from transplantation of tumor
biopsies into NOD/SCID mice
Li S, Hoog JW, Aft RL, Tao Y, Luo J, Lin L, Davies SR, Crowder RJ, Ellis MJ.
Washington University in St. Louis, St. Louis, MO. |
|
| |
|
|
| 3:45 |
42. The chemoresistant population of luminal subtype human breast
cancer cells expresses a basal phenotype
Kabos P, Dye WW, Elias A, Horwitz KB, Sartorius CA. University of Colorado
Denver AMC, Aurora, CO.
|
|
| |
|
|
| 4:00 |
43. Differential Wnt pathway activation in triple negative breast
cancers comparative to HER2 and hormone positive breast cancers
identified from formalin-fixed, paraffin-embedded tissues
Barwick BG, Abramovitz M, Tang W, Kodani M, Oprea GM, De PK, Dey
N, Catzavelos C, Bouzyk M, Moreno CS, Leyland-Jones B. Winship Cancer
Institute, Atlanta, GA; VM Institue of Research, Montreal, Canada. |
|
| |
|
|
| 4:15 |
44. The effect of zoledronic acid on aromatase inhibitor associated
bone loss in postmenopausal women with early breast cancer
receiving adjuvant letrozole: 36 months follow-up of ZO-FAST
Eidtmann H, Bundred NJ, DeBoer R, Llombart A, Davidson N, Neven P,
von Minckwitz G, Miller J, Schenk N, Coleman R. University Frauenklinik,
Kiel, Germany; South Manchester University Hospital, Manchester,
United Kingdom; Royal Melbourne Hospital, Victoria, Australia; Institute
Oncologica, Valencia, Spain; Broomfield Hospital, Chelmsford Essex, United
Kingdom; Hospital Gasthuisberg, Leuven, Belgium; German Breast Group,
Frankurt, Germany; Novartis, Florham Park, NJ; Weston Park Hospital,
Sheffield, United Kingdom. |
|
| |
|
|
| 4:30 |
45. Chromosome 17 polysomy (Ch17) as a predictor
of anthracycline response: Emerging evidence from
the UK NEAT adjuvant breast cancer Trial
Bartlett JMS, Munro A, Dunn JA, Hiller L, Twelves CJ,
Cameron DA, Thomas J, Campbell F, Provenzano
E, Pharoah P, Caldas C, Earl H, Poole CJ; Endocrine
Cancer Group, Edinburgh University, United Kingdom;
WMSCTU, University of Warwick, Coventry, United
Kingdom; University of Bradford, United Kingdom;
University of Leeds, United Kingdom; University of
Cambridge, United Kingdom; Addenbrookes Hospital,
Cambridge, United Kingdom; NIHR Cambridge
Biomedical Research Centre, Cambridge, United
Kingdom; University of Birmingham, United Kingdom.
|
|
| |
|
|
| 4:45 |
46. Lapatinib Combined with Letrozole vs. Letrozole
Alone for Front Line Postmenopausal Hormone
Receptor Positive (HR+) Metastatic Breast Cancer
(MBC): First Results from the EGF30008 Trial
Johnston S, Pegram M, Press M, Pippen J, Pivot X,
Gomez H, Florance A, O’Rourke L, Julie Maltzman J.
Royal Marsden NHS Foundation Trust & Institute
of Cancer Research, London, UK; Department of
Medicine, University of Miami, Miami, FL; USC/Norris
Comprehensive Cancer Center, Los Angeles, CA;
US Oncology Research Inc, Houston, TX; University
Hospital J. Minjoz, Besancon, France; Instituto De
Enfermedades Neoplasicas, Lima, Peru; GlaxoSmithKline
Oncology, Collegeville, PA.
|
|
| |
|
|
| 5:00-7:00 |
POSTER DISCUSSION SESSION 5 & RECEPTION –
Ballroom A |
|
| |
Risk & Prevention |
501-507 |
| |
|
|
| 5:00-7:00 |
POSTER DISCUSSION SESSION 6 & RECEPTION – Ballroom B |
|
| |
ER/PR Coregulators |
601-607 |
| |
|
|
| 5:00-7:00 |
POSTER SESSION 3 & RECEPTION – Exhibit Hall B
(#3001-3160) |
|
| |
|
|
| |
Detection/Diagnosis
Diagnostic Pathology
|
3001-3015
|
| |
|
|
| |
Tumor Cell and Molecular Biology
Apoptosis and Senescence
Endocrine Therapy and Resistance
Hormonal Factors and Receptors
Novel/Emerging Therapeutic Targets
Virology
|
3016-3019
3020-3040
3041-3058
3059-3082
3083-3087 |
| |
|
|
| |
Risk, Epidemiology and Prevention
Epidemiology - Genetic and Molecular
Other
|
3088-3099
3100-3104 |
| |
|
|
| |
Social, Behavioral, Economic and Outreach Studies
Palliation and Support (Pain Management)
Psychosocial Aspects
Other
|
3105
3106-3110
3111-3117
|
| |
|
|
| |
Treatment
Advanced Therapy - Targeted
Alternative Therapies
Her2-Targeted Therapy (Adjuvant and Metastatic)
|
3118-3126
3127-3130
3131-3160
|
| |
|
|
|
Home
